This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Cordycepin
- DrugBank Accession Number
- DB12156
- Background
Cordycepin has been used in trials studying the treatment of Leukemia.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Cordycepin (DB12156)
- Weight
- Average: 251.2419
Monoisotopic: 251.101839307 - Chemical Formula
- C10H13N5O3
- Synonyms
- Not Available
- External IDs
- NSC-401022
- NSC-63984
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcenocoumarol The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Cordycepin. Ambroxol The risk or severity of methemoglobinemia can be increased when Cordycepin is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Cordycepin is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when Cordycepin is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Cordycepin is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when Cordycepin is combined with Bupivacaine. Butacaine The risk or severity of methemoglobinemia can be increased when Cordycepin is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Cordycepin is combined with Butamben. Capsaicin The risk or severity of methemoglobinemia can be increased when Cordycepin is combined with Capsaicin. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Cordycepin is combined with Chloroprocaine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as purine 3'-deoxyribonucleosides. These are compounds consisting of a purine linked to a ribose which lacks a hydroxyl group at position 3.
- Kingdom
- Organic compounds
- Super Class
- Nucleosides, nucleotides, and analogues
- Class
- Purine nucleosides
- Sub Class
- Purine 3'-deoxyribonucleosides
- Direct Parent
- Purine 3'-deoxyribonucleosides
- Alternative Parents
- 6-aminopurines / Aminopyrimidines and derivatives / N-substituted imidazoles / Imidolactams / Tetrahydrofurans / Heteroaromatic compounds / Secondary alcohols / Oxacyclic compounds / Azacyclic compounds / Primary amines show 3 more
- Substituents
- 6-aminopurine / Alcohol / Amine / Aminopyrimidine / Aromatic heteropolycyclic compound / Azacycle / Azole / Heteroaromatic compound / Hydrocarbon derivative / Imidazole show 17 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- adenosines, 3'-deoxyribonucleoside (CHEBI:29014)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- GZ8VF4M2J8
- CAS number
- 73-03-0
- InChI Key
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N
- InChI
- InChI=1S/C10H13N5O3/c11-8-7-9(13-3-12-8)15(4-14-7)10-6(17)1-5(2-16)18-10/h3-6,10,16-17H,1-2H2,(H2,11,12,13)/t5-,6+,10+/m0/s1
- IUPAC Name
- (2R,3R,5S)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolan-3-ol
- SMILES
- [H][C@@]1(CO)C[C@@]([H])(O)[C@@]([H])(O1)N1C=NC2=C(N)N=CN=C12
References
- General References
- Not Available
- External Links
- KEGG Compound
- C08431
- PubChem Compound
- 6303
- PubChem Substance
- 347828450
- ChemSpider
- 6064
- BindingDB
- 50144950
- 1989289
- ChEBI
- 29014
- ChEMBL
- CHEMBL305686
- ZINC
- ZINC000001319796
- PDBe Ligand
- 3AD
- Wikipedia
- Cordycepin
- PDB Entries
- 1fa0 / 3b4b / 3b4c / 3onf / 5m5k / 6f3p
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Treatment Leukemias 1 1, 2 Unknown Status Treatment Refractory TdT-Positive Leukemia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 11.3 mg/mL ALOGPS logP -0.85 ALOGPS logP -1.4 Chemaxon logS -1.4 ALOGPS pKa (Strongest Acidic) 13.53 Chemaxon pKa (Strongest Basic) 3.94 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 119.31 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 62.1 m3·mol-1 Chemaxon Polarizability 24.15 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 20, 2016 21:29 / Updated at June 12, 2020 16:53